Arch Therapeutics, Inc. (ARTH)

Arch Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Year Ending	TTM	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019
Net Income	-8.43	-6.98	-5.28	-6.24	-4.69	-4.55
Depreciation & Amortization	0	0	0	0	0.01	0.01
Other Amortization	2.9	2.31	0.3	-	-	-
Stock-Based Compensation	0.1	0.25	0.5	0.5	0.9	1.23
Other Operating Activities	-	-1.16	-0.75	-0.11	-0.62	-1.82
Change in Inventory	0.07	0.05	-0.57	-0.31	-0.68	-0.35
Change in Accounts Payable	0.54	0.98	0.85	0.07	-0.19	0.37
Change in Other Net Operating Assets	1.12	1.18	0.49	0.13	0.23	-0.16
Operating Cash Flow	-3.69	-3.37	-4.46	-5.96	-5.04	-5.27
Capital Expenditures	-0	-0	-	-0	-0	-
Investing Cash Flow	-0	-0	-	-0	-0	-
Long-Term Debt Issued	-	1	3.04	1.05	0.73	-
Total Debt Issued	1.83	1	3.04	1.05	0.73	-
Short-Term Debt Repaid	-	-0.35	-0.11	-	-	-
Total Debt Repaid	-0.35	-0.35	-0.11	-	-	-
Net Debt Issued (Repaid)	1.48	0.64	2.94	1.05	0.73	-
Issuance of Common Stock	2.21	2.21	-	6.22	3.1	1.15
Other Financing Activities	-	-	-	-	-	1.63
Financing Cash Flow	3.69	2.85	2.94	7.27	3.83	2.78
Net Cash Flow	-0	-0.52	-1.52	1.31	-1.22	-2.49
Free Cash Flow	-3.69	-3.38	-4.46	-5.96	-5.05	-5.27
Free Cash Flow Margin	-2827.86%	-4461.91%	-28469.68%	-51551.26%	-	-
Free Cash Flow Per Share	-0.78	-1.10	-3.71	-5.42	-5.37	-6.33
Levered Free Cash Flow	-1.14	-1.34	-2.52	-2.63	-3	-2.88
Unlevered Free Cash Flow	-1.72	-1.71	-2.47	-2.53	-2.98	-2.88
Change in Net Working Capital	-1.13	-1.19	-0.59	-0.96	0.64	0.13

Source: S&P Capital IQ. Standard template.